Analysis snapshotSnapshot decision:REVIEW

Sebia CAPILLARYS 2 FLEX-PIERCING Pair — GSA Auction Analysis

Two photo-identified Sebia CAPILLARYS 2 FLEX-PIERCING analyzers retain specialist recovery potential, but seller-declared scrap, missing parts, no PC/PHORESIS environment, no functional evidence, and buyer-managed two-unit freight leave no positive blind/as-is hammer.

Stale-data warning

Analysis snapshot · Open at observation — observed September 22, 2026. This is an immutable observation, not a live feed. The auction is scheduled to close October 13, 2026. Price, status, close time, and terms may have changed. Check the source auction before bidding.

Decision at a glance

RecommendationREVIEW
Maximum hammer bid
$0

The auction bid ceiling supported by this analysis, if one is defensible; see costs below for buyer-premium treatment.

Why this decision

REVIEW: exact identity and residual market evidence do not overcome explicit scrap/parts-missing condition, unbounded workflow completeness, and two-unit recovery costs; the blind/as-is ceiling is $0.

What to verify before bidding

  • Seller-declared missing parts and no PC/PHORESIS environment can prevent recovery of either complete system.
  • No functional evidence supports capillary separation, fluidics, detection, temperature control, or analytical-output claims.
Review all risks and unknowns

See costs and maximum bid for the displayed assumptions and buyer-premium treatment.

Snapshot auction result
Not captured
Bidders
Not captured
Blind-model resale
$2,500
Snapshot provenance and timing · observed Sep 22, 2026, 6:17 AM UTC · scheduled close October 13, 2026

GSA Auctions sale 4-1-QSC-I-27-005, lot 011 · Los Angeles, California 90049
Snapshot observed Sep 22, 2026, 6:17 AM UTC
Scheduled close October 13, 2026
Analysis prepared Sep 22, 2026, 6:17 AM UTC
Published September 22, 2026 · page updated September 22, 2026

Prepared and published by Oleksii Udod for LotCaliper.

These are individually prepared, time-stamped analyses with recorded scheduled closes. Verify the official auction before acting.

Auction snapshot

This page preserves the September 22, 2026 GSA pre-close observation for item 377707, sale 4-1-QSC-I-27-005, lot 011. No numeric high bid or bidder count was preserved; blank fields are not a $0 result. The scheduled close is recorded as the date-only October 13 marker, not an exact auction clock time.

A specific electrophoresis identity is not the same as a complete PC/software, rack, reagent, and analytical workflow.

Review and correction history

Independent review not required. No corrections recorded.

View review and correction details

Independent review not required

No mandatory independent review was required under the current gate. This is not an approval.

How independent review works
How evidence is classified

Seller facts, photo-derived observations, manufacturer context, unknowns, and LotCaliper assumptions remain explicitly separated.

Source Confirmed

Seller-confirmed

  • The lot contains two CAPILLARYS 2 FLEX-PIERCING analyzers, with EE177246 / SN 96334 and EE177247 / SN 96333 labels.
  • The seller calls the lot blood chemistry analyzers and states scrap condition, missing parts, repairs required, fair wear, and outdated status.

Photo Derived

Photo-derived

  • Main analyzer/reagent-fluidics housings and biomedical-engineering PM labels are visible, but neither proves complete internal configuration or function.

Not Established

Not established

  • No complete control environment, PHORESIS software, racks, reagents/consumables, power-on, capillary performance, fluidics, detection, or complete accessory inventory is established.

Manufacturer Context

Independent context

  • FDA records identify the platform as an eight-capillary electrophoresis system with PC interface, PHORESIS software, rack workflow, deuterium-lamp detection, and Peltier temperature control.

Lotcaliper Assumption

LotCaliper assumptions

  • $2,500 conservative whole-lot specialist resale after economical sorting and verification; it is not two complete working-system values.
  • $0 blind/as-is hammer after selling friction, two-unit freight, testing, PC/software/rack recovery, repair, and standard-return reserves.
Structured photo observations (1)

These are bounded observations from the preserved photographs. They do not establish functional operation or seller inclusion beyond the corresponding source evidence.

Model · Confirmed

Supplied manufacturer and asset labels identify two Sebia CAPILLARYS 2 FLEX-PIERCING analyzers: EE177246 / SN 96334 and EE177247 / SN 96333; the former plate shows 2018/03 manufacture.

Photo confidence: High

Equipment identity

Laboratory · quantity 2

Sebia CAPILLARYS 2 FLEX-PIERCING capillary-electrophoresis analyzers

Identity confidence: High

Identity evidence
  • Supplied manufacturer and asset labels identify two Sebia CAPILLARYS 2 FLEX-PIERCING analyzers: EE177246 / SN 96334 and EE177247 / SN 96333; the former plate shows 2018/03 manufacture.

    GSA Auctions · Image · observed Sep 22, 2026, 6:17 AM UTC

Configuration

Control PCs, PHORESIS software, racks, reagents, consumables, cables, and exact missing-part scope

Not established · no source evidence establishes presence or absence

Configuration evidence
  • No complete control environment, PHORESIS software, racks, reagents/consumables, power-on, capillary performance, fluidics, detection, or complete accessory inventory is established.

    GSA Auctions · Image · observed Sep 22, 2026, 6:17 AM UTC

Condition

As-is / repair risk

Seller states scrap condition, missing parts, and required repairs; no functional evidence is established.

Evidence confidence: High

Condition evidence
  • Seller-stated scrap, missing-parts, and repair-required condition.

    GSA Auctions · Text · observed Sep 22, 2026, 6:17 AM UTC

Untested

No complete control environment, PHORESIS software, racks, reagents/consumables, power-on, capillary performance, fluidics, detection, or complete accessory inventory is established.

Evidence confidence: High

Condition evidence
  • No complete control environment, PHORESIS software, racks, reagents/consumables, power-on, capillary performance, fluidics, detection, or complete accessory inventory is established.

    GSA Auctions · Image · observed Sep 22, 2026, 6:17 AM UTC

Market evidence

Market evidence strength

Medium Low

Public auditability

Full

Evidence recency

Mixed

Current exact-model asking and sold-out references establish a market but no qualified recent exact-model realized resale; asking and sold-out references are not treated as completed sales.

Model matchEvidence typeTreatmentCount
Exact ModelAskingUsed In Valuation3
Exact ModelAskingContext Only1
Exact ModelEnded Non RealizedContext Only1
SourceEvidenceObservedPriceRelevance and treatment
DOTmed CAPILLARYS 2 5887634

Marketplace

Asking

Exact Model

September 22, 2026$599

Powers-on exact-model unit with otherwise limited testing.

Used In Valuation

eBay CAPILLARYS 2 116818043894

Marketplace

Asking

Exact Model

September 22, 2026$599

Powers-on-only exact model with 60-day testing warranty.

Used In Valuation

eBay CAPILLARYS 2 297894044299

Marketplace

Asking

Exact Model

September 22, 2026$1,000

Powers on, difficult power switch, otherwise untested and sold as-is/parts.

Used In Valuation

eBay CAPILLARYS 2 226377196958

Marketplace

Asking

Exact Model

September 22, 2026$3,199

Parts/not-working as-is ask illustrating wide dispersion.

Context Only

BS Medical CAPILLARYS 2

Dealer

Ended Non Realized

Exact Model

September 22, 2026$1,600

Sold-out dealer page for seller-described tested/working-excellent equipment; not proof of sale at the listed price.

Context Only

Sensitivity and robustness

Requires Verification

The scenarios show potentially workable economics, but the stated verification gate must be resolved before bidding responsibly.

Blind/as-is standard profile

Max hammer
$0
Gross resale model
$1,500–$2,500

Both standard return requirements fail at a positive hammer under the approved blind/as-is cost model.

Verified-complete case

Max hammer
$0
Gross resale model
$2,500–$5,000

A positive verified-case ceiling requires both systems to power on, communicate with usable PHORESIS workstations, retain major racks/accessories, and pass relevant functional checks.

Costs and maximum bid

Transaction / operating costAmountBasis
Selling Fees$375LotCaliper assumption: 15% of modeled gross resale.
Shipping$900LotCaliper pickup, packing, rigging, and inbound-logistics reserve; not a carrier or GSA quote.
Testing Repair Reserve$400LotCaliper functional-test and diagnostic reserve.
Risk Buffer$600LotCaliper reserve for buyer-managed removal, untested scrap condition, missing parts, configuration recovery, repair, and resale uncertainty.
Other$500LotCaliper missing-component, configuration, or recovery reserve; not a seller or service quote.
Buyer premium
Not modeled
Return requirements
$500 minimum profit · 30% minimum ROI
Computed bid constraints

Profit floor: $0

ROI floor: $0

Binding: Profit and ROI floors

Snapshot blind/as-is max hammer
$0
Modeled result at recorded bid
No bid recorded

This is a reseller ceiling, not a prediction of the auction's closing price. Any buyer premium or other unquoted acquisition charge must be deducted before bidding.

Configuration, functional proof, and blind economics

The public identity uses the specific CAPILLARYS 2 FLEX-PIERCING electrophoresis designation while preserving the seller's generic blood-chemistry classification as a listing issue.

Visible PM labels are service-history clues only. They do not establish startup, PHORESIS communication, rack transport, capillary integrity, fluidics, detection, temperature control, or a valid electropherogram.

  • Power on both analyzers and verify a compatible PC/PHORESIS environment before assigning working-system value.
  • Inventory missing parts, racks, accessories, and fluidics hardware; obtain freight terms for two approximately 50 kg analyzers.

Recommendation and rationale

Snapshot decision

REVIEW

REVIEW: exact identity and residual market evidence do not overcome explicit scrap/parts-missing condition, unbounded workflow completeness, and two-unit recovery costs; the blind/as-is ceiling is $0.

Confidence

Identity
High
Configuration
Medium Low
Condition
Low
Market Support
Medium Low
Costs
Low Medium
Why these confidence levels were assigned
Identity rationale
Supplied manufacturer and asset labels identify two Sebia CAPILLARYS 2 FLEX-PIERCING analyzers: EE177246 / SN 96334 and EE177247 / SN 96333; the former plate shows 2018/03 manufacture.
Configuration rationale
No complete control environment, PHORESIS software, racks, reagents/consumables, power-on, capillary performance, fluidics, detection, or complete accessory inventory is established.
Material unknowns: Unbounded
Condition rationale
Seller scrap/repair wording controls; no power-on or functional evidence is supplied.
Material unknowns: Unbounded
Market Support rationale
Current exact-model asking and sold-out references establish a market but no qualified recent exact-model realized resale; asking and sold-out references are not treated as completed sales.
Material unknowns: Bounded
Costs rationale
Buyer-managed removal is established, while actual freight, recovery, and repair costs remain unquoted.
Material unknowns: Unbounded

Market support assesses how well the available evidence supports the resale assumption. Exact third-party marketplace records may be omitted when source-use rights are unclear. Each dimension uses the published methodology rubric; a confidence label measures the strength and boundedness of its evidence, not the likelihood of a profitable outcome.

Risks and unknowns

High · Missing Components

Seller-declared missing parts and no PC/PHORESIS environment can prevent recovery of either complete system.

The approved snapshot provides no evidence sufficient to remove this resale-critical uncertainty.

High · Functionality Unverified

No functional evidence supports capillary separation, fluidics, detection, temperature control, or analytical-output claims.

The approved snapshot provides no evidence sufficient to remove this resale-critical uncertainty.

Sources

View cited public sources